Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Trial of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L) in Individuals With Schizophrenia or Schizoaffective Disorder at Risk for Treatment Non-adherence and for Homelessness
Brief Summary: Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%. Inadequate adherence is associated with poor outcomes such as relapse, homelessness, hospitalization, and increased health care costs. Studies have shown a direct correlation between non-adherence and rates of relapse in schizophrenia; on average, non-adherent patients have a risk of relapse that is 3.7 times greater than their adherent counterparts. A major obstacle to good outcomes in the maintenance treatment of patients with severe mental illness is difficulty with medication routines on an on-going basis. For this reason, long-acting injectable antipsychotic medication is a particularly attractive treatment option for populations with schizophrenia and schizoaffective disorder, although it is unlikely that medication treatment alone is likely to modify long-term attitudes and behaviors.

This prospective study is a pilot analysis of a combined approach which merges a psychosocial intervention to optimize treatment attitudes towards psychotropic medication (CAE) and long-acting injectable antipsychotic medication (L) in recently homeless individuals with schizophrenia or schizoaffective disorder who are known to have on-going difficulties with treatment non-adherence. It is expected that this combined approach (CAE-L) will improve illness outcomes among the most vulnerable of populations with schizophrenia or schizoaffective disorder.


Options:
A: Arm Label: FEM-CARE; Type: EXPERIMENTAL; Interventions: Behavioral: FEM-CARE | Arm Label: Health Promotion; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Promotion | Intervention Type: BEHAVIORAL; Name: FEM-CARE; Assigned to Arm(s): FEM-CARE | Intervention Type: BEHAVIORAL; Name: Health Promotion; Assigned to Arm(s): Health Promotion
B: Arm Label: SBIRT Group; Type: EXPERIMENTAL; Interventions: Behavioral: SBIRT | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Group | Intervention Type: BEHAVIORAL; Name: SBIRT; Assigned to Arm(s): SBIRT Group | Intervention Type: BEHAVIORAL; Name: Control Group; Assigned to Arm(s): Control Group
C: Arm Label: Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing | Arm Label: Supervision As Usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Motivational Computer; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Computer | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Motivational Computer; Assigned to Arm(s): Motivational Computer
D: Arm Label: Patient Noncompliance; Type: EXPERIMENTAL; Interventions: Drug: haloperidol decanoate, Drug: haloperidol, Behavioral: Customized Adherence Enhancement | Intervention Type: DRUG; Name: haloperidol decanoate; Assigned to Arm(s): Patient Noncompliance | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): Patient Noncompliance | Intervention Type: BEHAVIORAL; Name: Customized Adherence Enhancement; Assigned to Arm(s): Patient Noncompliance

Answer: D